全文获取类型
收费全文 | 187374篇 |
免费 | 34277篇 |
国内免费 | 2603篇 |
专业分类
耳鼻咽喉 | 5625篇 |
儿科学 | 6029篇 |
妇产科学 | 2989篇 |
基础医学 | 8015篇 |
口腔科学 | 2741篇 |
临床医学 | 29380篇 |
内科学 | 56645篇 |
皮肤病学 | 8283篇 |
神经病学 | 17521篇 |
特种医学 | 7894篇 |
外科学 | 47251篇 |
综合类 | 481篇 |
现状与发展 | 72篇 |
一般理论 | 2篇 |
预防医学 | 8101篇 |
眼科学 | 3943篇 |
药学 | 3526篇 |
中国医学 | 62篇 |
肿瘤学 | 15694篇 |
出版年
2024年 | 524篇 |
2023年 | 4938篇 |
2022年 | 1516篇 |
2021年 | 3842篇 |
2020年 | 6381篇 |
2019年 | 2685篇 |
2018年 | 8093篇 |
2017年 | 7871篇 |
2016年 | 9018篇 |
2015年 | 9096篇 |
2014年 | 16377篇 |
2013年 | 16602篇 |
2012年 | 7114篇 |
2011年 | 7256篇 |
2010年 | 11276篇 |
2009年 | 15154篇 |
2008年 | 7457篇 |
2007年 | 5795篇 |
2006年 | 8280篇 |
2005年 | 5602篇 |
2004年 | 4821篇 |
2003年 | 3719篇 |
2002年 | 3800篇 |
2001年 | 5044篇 |
2000年 | 4423篇 |
1999年 | 4451篇 |
1998年 | 4121篇 |
1997年 | 3806篇 |
1996年 | 3705篇 |
1995年 | 3546篇 |
1994年 | 2230篇 |
1993年 | 1813篇 |
1992年 | 2202篇 |
1991年 | 2175篇 |
1990年 | 1751篇 |
1989年 | 1876篇 |
1988年 | 1702篇 |
1987年 | 1523篇 |
1986年 | 1556篇 |
1985年 | 1310篇 |
1984年 | 981篇 |
1983年 | 875篇 |
1982年 | 690篇 |
1981年 | 557篇 |
1980年 | 494篇 |
1979年 | 650篇 |
1978年 | 565篇 |
1977年 | 598篇 |
1975年 | 478篇 |
1972年 | 501篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
101.
Fibromyalgia is a syndrome of widespread pain, nonrestorative sleep, disturbed mood, and fatigue. Optimal treatment involves
a multidisciplinary approach with a team of health care providers using pharmacologic and nonpharmacologic treatment. Because
of the heterogeneity of the illness, management should be individualized for the patient. Pharmacologic treatment should address
issues of pain control, sleep disturbance, fatigue, and any underlying coexisting mood disorder. Nonpharmacologic treatment
should include patient education, a regular exercise and stretching program, and cognitive behavioral therapy. All of these
are essential to improving functional capacity and quality of life. This review provides general guidelines in initiating
a successful pharmacologic treatment program for patients with fibromyalgia. 相似文献
102.
The clinical syndrome of tuberculous (TB) meningitis leading to ischemic strokes is rarely seen today in immunocompetent adults native to North America. This entity is also notoriously difficult to diagnose because the presenting symptoms are often nonspecific. The authors describe a case of a man with TB meningitis which progressed to recurrent ischemic cerebral infarcts. 相似文献
103.
104.
105.
106.
107.
Toshio Kushiro Hiroshige Itakura Yoshihisa Abo Hiromi Gotou Shinji Terao Deborah L Keefe 《Hypertension research》2006,29(12):997-1005
Aliskiren is a novel orally active renin inhibitor for the treatment of hypertension. This study evaluated the antihypertensive efficacy, safety and tolerability of aliskiren in Japanese patients with hypertension. Forty hundred and fifty-five Japanese men and women with a mean sitting diastolic blood pressure of 95-110 mmHg were randomized to receive once-daily double-blind treatment for 8 weeks with aliskiren 75, 150 or 300 mg or placebo. Aliskiren produced significant, dose-dependent reductions in mean sitting diastolic blood pressure (p<0.0005 vs. placebo for each dose) and mean sitting systolic blood pressure (p<0.001 vs. placebo for each dose). The placebo-corrected reductions in mean sitting systolic/diastolic blood pressure were 5.7/4.0, 5.9/4.5 and 11.2/7.5 mmHg in the aliskiren 75, 150 and 300 mg groups, respectively. After 8 weeks' treatment, 27.8%, 47.8%, 48.2% and 63.7% of patients in the placebo and aliskiren 75, 150 and 300 mg groups, respectively, achieved a successful treatment response (diastolic blood pressure <90 mmHg and/or reduced by > or =10 mmHg from baseline; p<0.005 vs. placebo for each dose). Aliskiren treatment was well tolerated, with the incidence of adverse events reported in the active treatment groups (53-55%) being similar to that in the placebo group (50%). This study, which is the first to assess the antihypertensive efficacy and safety of aliskiren in Japanese patients with hypertension, demonstrates that the once-daily oral renin inhibitor aliskiren provides significant, dose-dependent reductions in blood pressure with placebo-like tolerability. 相似文献
108.
Bo Jørgensen MD ; Gitte Juel Friis PhD ; Finn Gottrup MD DMSci 《Wound repair and regeneration》2006,14(3):233-239
Wound pain is a serious problem for elderly patients suffering from chronic leg ulcers, and it may lead to reduced wound healing rates and reduced quality of life. Biatain-Ibu Non-adhesive (Coloplast A/S), a new pain-reducing moist wound healing dressing containing ibuprofen was tested for pain reduction, safety, and efficacy on 10+2 patients in a single-blinded crossover study against Biatain Non-adhesive (Coloplast A/S). Pain was measured with a Numeric Box Scale before, during, and after dressing change. Quality of life was measured using the World Health Organization-5 Well-Being Index. Dressing moist wound healing properties such as absorption capacity and leakage were tested together with assessment of wound exudate and blood plasma content of ibuprofen. Use of the Biatain-Ibu foam dressing correlated with a decrease in pain intensity scores from 7 in the run-in period to approximately 2.5 in the Biatain-Ibu treatment phase. Quality of life measures were improved which together with the reduced pain could contribute to faster wound healing. The moist wound healing properties of Biatain-Ibu were similar to that of the Biatain Non-adhesive and ulcer size was reduced by 24% during the treatment period. Neither side effects nor systemic plasma concentrations of ibuprofen were observed. These data indicate that Biatain-Ibu could reduce persistent and temporary wound pain, increase Quality of life, was found safe to use, and had excellent moist wound healing properties. 相似文献
109.
110.